Dr Reddy’s is collaborating with innovator firms in China, Israel and the US largely in areas of unmet need, propelling its “Horizon-2” strategy that encompasses segments like biologics and cell and gene therapy, digital services and immuno-oncology NCEs, among others.

Dr Reddy’s is collaborating with innovator firms in China, Israel and the US largely in areas of unmet need, propelling its “Horizon-2” strategy that encompasses segments like biologics and cell and gene therapy, digital services and immuno-oncology NCEs, among others.

AvroBio retains rights to its other HSC gene therapy candidates. Alimera Acquires Further Commercial Rights To Eyepoint’s Uveitis Drug.

Fresenius Kabi has switched from a geographic to segment-focused quarterly disclosure, in an attempt to improve transparency across its four key business units, three of which have been identified as key growth drivers.